about
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.Drug-drug interactions with imatinib: An observational study.Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database.Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants.Atropinic (Anticholinergic) Burden in Parkinson's Disease.Pharmacovigilance, risks and adverse effects of self-medication.Mania associated with ranitidine: a case report and review of literature.Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.Adverse drug reactions to self-medication: a study in a pharmacovigilance database.The contribution of pharmacogenetics to pharmacovigilance.Undesirable effects related to oral antineoplastic drugs: comparison between patients' internet narratives and a national pharmacovigilance database.Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database.Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase® , the WHO pharmacovigilance database.Gingival bleeding, a possible "serious" adverse drug reaction: An observational study in the French PharmacoVigilance Database.Statins and diabetes: is there any difference between the different statins?Pulmonary arterial hypertension and benfluorex: 5 case reports.Use of administrative hospital database to identify adverse drug reactions in a Pediatric University Hospital.A comparative study of QT prolongation with serotonin reuptake inhibitors.Effets indésirables cutanés sous cetuximab en conditions réelles d’utilisation : indicateur d’efficacité pour les cancers colorectaux métastatiques et les cancers des voies aérodigestives supérieures ?The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in FranceHemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA)Acute Coronary Syndrome After Nasal Spray of OxymetazolineInhaled corticosteroid-induced hair depigmentation in a childDrug-induced gingival overgrowth: a study in the French Pharmacovigilance DatabaseSevere intracranial bleeding related to vitamin K Antagonist-Ropinirole interaction
P50
Q35085772-AF065D14-9D8A-402E-944F-6A49A9EAAE80Q37328934-AB23648D-7D33-423D-8DF6-0A52C15C414AQ37889802-5760EEEF-B4C5-45ED-871D-BDCBAB03A6A4Q38058214-B60BDAE2-B4DA-45EA-8EFB-CA662507538BQ38073712-CC52CE77-A79A-49B9-82AF-53AA03AF5659Q38297244-E91990DE-F977-43DC-A01F-CB04F23E795BQ38793600-49E09215-5FAF-43D5-86EE-631C22EA2294Q38808896-AC02BA57-867F-4D51-9FD8-D321119FD8D9Q38809383-D3C37D8A-61FF-43C2-843A-ED84A63AC7ACQ39014995-6A6CA73F-CB57-4025-A73F-8903F220166CQ39043874-5BF2BF26-5040-497D-9C63-B696102C6D34Q39336264-F8C30F0A-5886-418E-8957-F869ADE5A7A0Q40690768-C70E06EC-EB2C-4D98-80DA-CCBE8A27394CQ40713413-C72E326C-A435-4AC2-996F-63FAFDD9D353Q42672233-FF8E42F5-AE4C-4414-8785-1F6B8EB540D0Q42952828-E87A2120-86C4-4E22-BF38-6F87E0CE6DC3Q42997648-6FB6994E-4912-494C-A7F5-7E151B7972D5Q43958079-72F054B3-C21E-408D-8422-03E13F38BBFDQ44731914-FC4FA0D1-BBCC-4696-8421-0B5BF7E3A057Q45898539-2FAA3D8C-BAE2-4D86-B189-D22C6B50CC3EQ47779429-DA996DEC-BB5B-4A8B-B781-619170944BBBQ48190936-61FD634D-66FC-48C5-A2EB-0AC167F8BD7BQ48261639-88379914-C913-4512-851C-4C978327C601Q48299669-F82E60D7-A6FD-4A8F-92B9-DE748C228A13Q50623951-5972FEC3-2830-4848-8138-E81ACF02566BQ53811350-DBF974B2-3305-449A-8BEC-AD154F58FE79Q60619161-891C3F80-0436-411D-BB70-E07E50AF71FCQ60619178-6A6AD623-6EE7-42FA-B46C-64EF1D008ADAQ61314461-570F5961-E4E9-479E-9C69-8BC2F6768A17Q61314463-4EF79F93-A25F-4EB6-B8EB-37480B406A34Q61314468-CBB3BDC5-DBC9-4112-A96E-016A40B5A9FAQ61314471-65344B1E-70C8-4F0F-AF12-C4DD47DB8DD7Q61314473-39F41DF3-A8F5-4C60-BFFA-7424A2C742F3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emmanuelle Bondon-Guitton
@ast
Emmanuelle Bondon-Guitton
@en
Emmanuelle Bondon-Guitton
@es
Emmanuelle Bondon-Guitton
@nl
Emmanuelle Bondon-Guitton
@sl
type
label
Emmanuelle Bondon-Guitton
@ast
Emmanuelle Bondon-Guitton
@en
Emmanuelle Bondon-Guitton
@es
Emmanuelle Bondon-Guitton
@nl
Emmanuelle Bondon-Guitton
@sl
altLabel
Emmanuelle Guitton
@en
prefLabel
Emmanuelle Bondon-Guitton
@ast
Emmanuelle Bondon-Guitton
@en
Emmanuelle Bondon-Guitton
@es
Emmanuelle Bondon-Guitton
@nl
Emmanuelle Bondon-Guitton
@sl
P106
P21
P31
P496
0000-0002-1212-3898